After being told he might not walk for two years, the longtime Little League football coach fought through treatment to ...

Dr. Lin joins Nuvig to advance NVG-2089 through Phase 2 studies in chronic inflammatory demyelinating polyneuropathy and ...

VYVGART ® SC is first and only neonatal Fc receptor blocker approved to treat CIDP Authorization is based on global ADHERE study, the largest clinical trial in CIDP to date First novel, targeted ...

The prescribed dosage for Privigen (human immunoglobulin g) may vary depending on a person’s individual treatment plan. Other factors, including your specific diagnosis, body weight, and medical ...

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare but treatable condition. Although the symptoms — muscle weakness, numbness, tingling, and loss of coordination — can significantly ...

Living with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a journey that demands resilience, vigilance, and, most importantly, a robust support system. CIDP is a rare, complex, and ...

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

NVG-2089 is a recombinant Fc fusion protein designed to replicate key immunomodulatory functions of IVIg with greater consistency, scalability, and patient convenience Phase 1 data show NVG-2089 was ...